Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity

Blood

Volumn 119, Issue 20, 2012, Pages 4719-4722

  Bacher, Ulrike ^a   Schnittger, Susanne ^b   Macijewski, Katja ^b   Grossmann, Vera ^b   Kohlmann, Alexander ^b   Alpermann, Tamara ^b   Kowarsch, Andreas ^b   Nadarajah, Niroshan ^b   Kern, Wolfgang ^b   Haferlach, Claudia ^b   Haferlach, Torsten ^b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; FLT3 LIGAND;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CCAAT ENHANCER BINDING PROTEIN MUTATED ACUTE MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTILINEAGE DYSPLASIA; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; WORLD HEALTH ORGANIZATION;

EID: 84861214425     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-395574     Document Type: Article

References (17)

1. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009; 113(13):3088-3091.
2. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469-2475.
3. Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28(16):2739-2747.
4. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570-577.
5. Shen Y, Zhu Y, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1,185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-5603.
6. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood. 2009;113(21):5090-5093.
7. Schnittger S, Alpermann T, Eder C, et al. The role of different genetic subtypes in CEBPA mutated AML [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116;752.
8. Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109-1120.
9. Arber B, Brunning R, Le Beau M, Falini B. Acute myeloid leukemia with recurrent genetic abnormalities. In: Swerdlow S, Campo E, Harris NL, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th Ed. Lyon: World Health Organization; 2008:110-123.
10. Arber DA, Brunning RD, Orazi A, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow S, Campo E, Harris NL, eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th Ed. Geneva: World Health Organization; 2008:124-126.
11. Büchner T, Berdel W, Haferlach C, et al. Agerelated risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27(1):61-69.
12. Löffler H, Raststetter J, Haferlach T, eds. Atlas of Clinical Hematology. 6th Ed. Berlin: Springer-Verlag; 2004.
13. Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6(6):520-525.
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976;33(4): 451-458.
15. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-625.
16. Grimwade D, Hills R, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. 2010;116(3):354-365.
17. Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010; 115(18):3776-3786.